DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "World Ovarian Cancer Drugs Market - Opportunities and Forecasts, 2014 - 2022" report to their offering.
The market for ovarian cancer is segmented geographically into North America, Europe, Asia Pacific and LAMEA. North America is the major revenue generating market mainly due to the prevalence of ovarian cancer. According to the American cancer society, an estimated 21,980 women would be diagnosed with ovarian cancer in 2014 in the US. Europe is the second largest market as the incidence for ovarian cancer is high in Europe.
The market is driven by the increasing incidence of ovarian cancer. The need for more effective treatment options is pushing growth of the market. While the market is dominated by generics such as paclitaxel and carboplatin, it is expected that drugs such as Bevacizumab (Avastin), Pazopanib (Votrient) would boost the growth of this market. Development of drugs with improved efficacy is a challenge for this market. The opportunity for this market lies in developing new drugs for treating ovarian cancer.
The companies include Roche, Amgen, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and others. In Dec 2011, Roche received EU approval for it drug Avastin (bevacizumab) to be used in combination with carboplatin and paclitaxel as treatment for ovarian cancer.
Market analysis by porter's five-force model shows that the bargaining power of the buyer is high in this market as the market is dominated by generic drugs and there are many suppliers producing the drugs. The threat of new entrants is moderate as the drugs for treating ovarian cancer are mainly generic and pharmaceutical companies can easily start producing the drugs. Intensity of rivalry is high in this market as competitors are numerous and the drugs are undifferentiated. Top impacting factors have been given to get a clearer understanding of the market.
The ovarian cancer drug market is segmented by drugs:
- Adriamycin PFS (Doxorubicin Hydrochloride)
- Platinol (Cisplatin)
- Paraplatin (Carboplatin)
- Doxorubicin Hydrochloride Liposome
- Evacet (Doxorubicin Hydrochloride Liposome)
- Cytoxan (Cyclophosphamide)
- Paraplat (Carboplatin)
- Taxol (Paclitaxel)
- Neosar (Cyclophosphamide)
- Gemcitabine Hydrochloride
- Platinol-AQ (Cisplatin)
- Topotecan Hydrochloride
- Gemzar (Gemcitabine Hydrochloride)
- Hycamtin (Topotecan Hydrochloride)
- Doxorubicin Hydrochloride
- LipoDox (Doxorubicin Hydrochloride Liposome)
- Dox-SL (Doxorubicin Hydrochloride Liposome)
- Clafen (Cyclophosphamide)
- Adriamycin RDF (Doxorubicin Hydrochloride)
- DOXIL (Doxorubicin Hydrochloride Liposome)
For more information about this report visit http://www.researchandmarkets.com/research/hmxjf5/world_ovarian